Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer

Wang, Hsiu-Tzu; Bai, Li‐Yuan; Wang, Ying-Tso; Lin, Cheng‐Li; Yang, Horng Ren; Hsueh, Po-Ren; Cho, Der Yang

doi:10.1016/j.jfma.2023.01.012

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs can be divided into epithelial CTCs (ECTCs) with positive EpCAM and CK8/18/19 gene expression, mesenchymal CTCs (MCTCs) with positive Vimentin and Twist genes expression, and hybrid CTCs (HCTCs) with both lineage markers expression [23,24]. In addition, studies have indicated that patients with higher numbers of CTCs tend to have a poorer response to treatment and a shorter overall survival (OS) compared to those with lower number of CTCs [25,26].…”

Section: Introductionmentioning

confidence: 99%

The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer

Ye,

Yu,

Huang

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

Background Patients with breast cancer (BC) at advanced stages have poor outcomes because of high rate of recurrence and metastasis. Biomarkers for predicting prognosis remain to be explored. This study aimed to evaluate the relationships between circulating tumor cells (CTCs) and outcomes of BC patients. Patients and methods A total of 50 female were enrolled in this study. Their diagnoses were determined by clinical characteristics, image data, and clinical pathology. CTC subtypes and TOP2A gene expression on CTCs were detected by CanPatrol™ technology and triple color in situ RNA hybridization (RNA-ISH), which divided into epithelial CTCs (eCTCs), mesenchymal CTCs (MCTCs), and hybrid CTCs (HCTCs) based on their surface markers. Hormone receptor, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, was measured by immunohistochemistry (IHC) method before treatment. The risk factors for predicting recurrence and metastasis were calculated by COX risk regression model. The progression-free survival (PFS) of patients was determined using Kaplan–Meier survival curve. Results The patients with a large tumor size (≥ 3 cm) and advanced tumor node metastasis (TNM) stages had high total CTCs (TCTCs) (P < 0.05). These patients also had high TOP2A expression level. COX risk regression analysis indicated that TOP2A expression levels in TCTCs, ER + , HER-2 + , and TNM stages were critical risk factors for recurrence and metastasis of patients (P < 0.05). The PFS of patients with ≥ 5 TCTCs, ≥ 3 HCTCs, and positive TOP2A expression in ≥ 3 TCTCs was significantly longer than that in patient with < 5 TCTCs, < 3 HCTCs, and TOP2A expression in < 3 TCTCs (P < 0.05). In contrast, the PFS of patients with positive hormone receptors (ER + , PR + , HER-2 +) also was dramatically lived longer than that in patients with negative hormone receptor expression. Conclusions High TCTC, HCTCs, and positive TOP2A gene expression on CTCs were critical biomarkers for predicting outcomes of BC patients. Positive hormone receptor expression in BC patients has significant favor PFS.

show abstract